Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Anakinra Market Be Worth By 2029?

The market size for anakinra has experienced swift growth in the past few years. Projected to rise from $4.89 billion in 2024 to $5.46 billion in 2025, it is anticipated to expand at a compound annual growth rate (CAGR) of 11.8%. The expansion in the market during the historic period is largely due to several factors such as, an increase in occurrence of rheumatoid arthritis, the endorsement of anakinra in treating uncommon autoinflammatory conditions such as NOMID, a heightened awareness of biologics’ role in managing persistent inflammatory conditions, and a surge in the adoption of targeted therapies.

The market for anakinra is projected to experience significant expansion in the imminent years, with a forecasted size of “$8.6 billion in 2029” representing a compound annual growth rate (CAGR) of 12.0%. This predicted surge over the forecast period can be associated with expanded usage indications for anakinra, an intensified focus on tailored medical treatments, a growing occurrence of uncommon autoinflammatory disorders, progress in drug delivery systems, and increased health care availability in developing markets driving biologics demand. Notable trends anticipated during the forecast period involve the emergence of biosimilars and next-generation IL-1 inhibitors, the uptake of home-based and self-administered treatments, partnerships between biotech firms and educational establishments, and the application of digital health technologies to enhance patient compliance.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

What Underlying Factors Are Supporting The Anakinra Market Growth?

The increasing number of autoimmune disorder cases is predicted to boost the anakinra market’s expansion. Autoimmune disorders are conditions where the body’s immune system wrongly attacks and damages its own healthy tissues and organs, considering them as external threats. The surge in the number of these disorders is influenced by both genetic predisposition and environmental elements, such as contaminations, pollution, and shifts in diet, all of which play a part in this upsurge. Anakinra is utilized to manage autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thus reducing inflammation in problems like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, as per an Australian Institute of Health and Welfare’s report in June 2024, an organization based in Australia, the hospitalizations for rheumatoid arthritis was 10,000 in the year 2021-22, marking a 25% growth from the preceding year’s 8,000. This translates to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune disorders acts as a driving force for the anakinra market’s advancement.

How Is The Anakinra Market Organized By Different Segments?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

What Current And Upcoming Trends Are Shaping The Anakinra Market?

Significant organizations operating in the Anakinra market are achieving regulatory clearances to broaden their implications for novel therapeutic uses. Regulatory clearances denote formal permissions from government bodies that permit a drug to be marketed and prescribed for specific health conditions, following assessment of its safety, effectiveness, and quality. For example, in November 2022 the US governmental agency, Food and Drug Administration, provided Emergency Use Authorization (EUA) for Kineret (anakinra), designed to treat adult hospital patients with pneumonia related to COVID-19 and requiring additional oxygen, with the objective of mitigating the risk of acute respiratory failure. This authorization arose from the SAVE-MORE phase 3 trial, which indicated that earlier treatment with Kineret enhanced patient outcomes. Kineret functions by inhibiting cytokines IL-1a and IL-1ß, factors contributing to the hyperinflammatory reaction in severe COVID-19 instances. Although it hasn’t obtained full FDA approval for this indication, it has been authorized for temporary usage during the public health crisis.

Which Firms Are Making The Biggest Impact In The Anakinra Market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

Which Region Dominates The Anakinra Market Today?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model